Indian drug shares declined Wednesday following US President Trump’s tariff announcement. These proposed tariffs will significantly impact companies with substantial US revenue exposure. Analysts suggest investors should now focus on domestically oriented Indian pharmaceutical firms. The Nifty Pharma index saw a notable decrease, while the benchmark Nifty 50 also fell. Negotiations are expected given India’s vital role in supplying affordable medicines to the US.
Bluestone Jewellery shares rocket 36% in just three days after Q1 results. Can the momentum sustain?
BlueStone Jewellery shares have surged 36% in three trading sessions after the company’s strong Q1 results, which marked a return to profitability and robust revenue